AQW051

Phase 2Small molecule

Novartis

AQW051 is one of 52 small molecule programs targeting Memory Impairment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Memory ImpairmentActive, not recruiting

SchizophreniaActive, not recruiting

Memory ImpairmentPhase 2

Active, not recruiting

SchizophreniaPhase 2

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

4 2

Resotran

Takeda

Preclinical

1 3

Ozempic

Novo Nordisk

Preclinical

1 4

Zocor

OOrganon and Co

Preclinical

6 5

Depakote

Ibrance

AQW051

3 8

Lunesta

Akero Therapeutics

Preclinical

3 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Permax

VValeant Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizophrenia3 trials

A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients

Completed· Novartis logo

Novartis·Phase 2·NCT01730768·147 enrolled

Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

Completed· Novartis logo

Novartis·Phase 2·NCT01163227·57 enrolled

Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia

Completed· Novartis logo

Novartis·Phase 1/2·NCT00825539·68 enrolled

Memory Impairment1 trial

Effect of AQW051 in Patients With Memory Impairment

Terminated· Novartis logo

Novartis·Phase 2·NCT00582855·54 enrolled

Parkinson's Disease1 trial

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Completed· Novartis logo

Novartis·Phase 2·NCT01474421·71 enrolled

Tics1 trial

Effect of Food on the Pharmacokinetics of AQW051 in Japanese Healthy Male Subjects

Completed· Novartis logo

Novartis·Phase 1·NCT00409500·54 enrolled

Elderly1 trial

Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.

Completed· Novartis logo

Novartis·Phase 1·NCT00418002·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for AQW051. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AQW051 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AQW051. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

AQW051

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schizophrenia3 trials

Memory Impairment1 trial

Parkinson's Disease1 trial

Tics1 trial

Elderly1 trial

References

Drug Info

Quick Facts

Related News